Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
Advertisement
Articles by Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
2
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
3
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
4
The DTC GLP-1 Boom Solved Access. Can It Solve Adherence?
5